Nintedone 150

Avoid alcohol consumption during treatment with NINTEDONE 150, as both alcohol and Nintedanib are processed by the liver and combining them increases the risk of hepatic toxicity.

NINTEDONE 150 can cause severe fetal harm and birth defects. Highly effective contraception must be used during treatment and for at least 3 months after the last dose. Female patients of childbearing potential must undergo pregnancy testing prior to starting therapy.

It is unknown whether Nintedanib passes into human milk. Due to potential serious adverse reactions in nursing infants, breastfeeding should be discontinued during treatment with NINTEDONE 150.

NINTEDONE 150 may cause dizziness or nausea in some patients. Exercise caution when driving or operating machinery until you know how the medication affects you.

Generally safe in mild to moderate renal impairment. Patients with severe renal impairment should be closely monitored by their physician as clinical data in severe cases is limited.

Contraindicated in patients with moderate to severe hepatic impairment (Child-Pugh B or C). Liver enzyme levels (ALT, AST, and Bilirubin) must be evaluated prior to initiating treatment and monitored periodically during therapy.